rabbit anti na v 1 9 antibody (Alomone Labs)
Structured Review

Rabbit Anti Na V 1 9 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 22 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+na+v+1+9/Anti-SCN11A+(Nav1%2E9)+Antibody/pmc08929296-55-35-41
Average 94 stars, based on 22 article reviews
Images
1) Product Images from "Protein arginine methyltransferase 7 modulates neuronal excitability by interacting with Na V 1.9"
Article Title: Protein arginine methyltransferase 7 modulates neuronal excitability by interacting with Na V 1.9
Journal: Pain
doi: 10.1097/j.pain.0000000000002421
Figure Legend Snippet: Yeast two-hybrid screen to identify proteins that interacted with Na V 1.9. (A) Schematic structure of the Na V 1.9 channel. Residues 402 to 570 of mNa V 1.9 were used as bait for the yeast two-hybrid (Y2H) screen. (B) Location of the repeat-independent clones of PRMT7 identified by Y2H (blue lines, residues 594-692). The 2 domains (pink/green) and degrees of homology between full-length mouse and human PRMT7 are shown. (C) Residues 594 to 692 of mouse PRMT7 were purified from yeast clones for direct Y2H to confirm the interaction on QDO medium. (D) Amino acid sequence comparison of hLoop1 and mLoop1 using ClustalW (EMBL–European Bioinformatics Institute). Potential PRMT7 methylation motif, RXR, is boxed. PRMT7, protein arginine methyltransferase 7; QDO, quadruple dropout.
Techniques Used: Two Hybrid Screening, Clone Assay, Purification, Sequencing, Methylation
Figure Legend Snippet: Interaction and coexpression of Na V 1.9 with PRMT7. Interaction between hLoop1 and full-length hPRMT7 was analysed by GST pull-down assays (A) and reciprocal coimmunoprecipitation assays (B). (C) Interaction between the intracellular domains of hNa V 1.9 and hPRMT7 was examined by coimmunoprecipitation assays. (D) Interaction of mPRMT7 with mNa V 1.9 in mouse DRG tissues was assessed. Scn11a +/+ or Scn11a −/− mouse DRG tissue lysates were immunoprecipitated using anti-mPRMT7 antibodies and control IgG. The precipitates were immunoblotted with the indicated antibodies. (E) Immunohistochemical analysis of mPRMT7/mNa V 1.9 expression in mouse DRG sections. The sections were stained for mPRMT7 (red) and mNa V 1.9 (green) and DAPI (blue). mPRMT7 showed considerable colocalization with mNa V 1.9 in mouse DRG neurons. Scale bars, 50 μm. (F) Percentages of mPRMT7-positive and mNa V 1.9-positive neurons are shown. DAPI, 4,6-diamidino-2-phenylindole; DRG, dorsal root ganglion; GST, glutathione S-transferase; IgG, immunoglobulin G; hNa V 1.9, human hNa V 1.9; PRMT7, protein arginine methyltransferase 7.
Techniques Used: Immunoprecipitation, Immunohistochemical staining, Expressing, Staining
Figure Legend Snippet: Protein arginine methyltransferase 7 affects the current density of Na V 1.9 by promoting its accumulation on the cell membrane. (A) Representative whole-cell sodium currents evoked by voltage from Scn11a −/− mouse DRG neurons electroporated with SCN11A or SCN11A and PRMT7 . (B) Current–voltage relationships in the indicated experimental groups. The peak current density (normalized by membrane capacitance) was statistically analysed (mock, n = 15; hNa V 1.9, n = 25; and hNa V 1.9 + hPRMT7, n = 23), and significant differences were tested by two-way ANOVA, followed by a post hoc Bonferroni test; infection × voltage: F(32, 948) = 5.846, P < 0.0001; infection: F(2, 948) = 66.28, P < 0.0001; voltage: F(15, 948) = 19.39, P <0.0001; * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with the mock group. (C) Representative whole-cell mNa V 1.9 currents evoked by voltage from Scn11a +/+ mouse small DRG neurons treated without (control) or with DS-437. (D) Quantification of the peak mNa V 1.9 current density in the experimental and control groups (control, n = 16; 10 μM DS-437, n = 13; 100 μM DS-437, n = 19). Significant differences were tested by two-way ANOVA, followed by a post hoc Bonferroni test; DS-437 × voltage: F(30, 693) = 3.237, P < 0.0001; DS-437: F(2, 693) = 27.49, P < 0.0001; voltage: F(15, 693) = 79.98, P < 0.0001; *** P < 0.001 compared with the control. (E) Schematic representation of the chimeric proteins. (F) HEK293T cells transiently expressing HA-CD4-hLoop1 and GFP-hPRMT7 or mock-transfected GFP cells were harvested and lysed, the whole-cell lysates (WCLs) were cleared of debris, and the postnuclear supernatant was fractionated into the membrane (Mem) and cytosolic (Cyto) fractions with a kit. Aliquots from all stages of fractionation were analysed by immunoblotting with the indicated antibodies. Na + K + -ATPase was used as a cell-surface–protein control. Quantification of Western blotting data showed that hPRMT7 significantly increased the amount of chimeras in plasma membranes (G) but did not affect the total expression level of the chimeric proteins (H). Data were statistically analysed by the unpaired Student t test; * P < 0.05 compared with GFP. All studies were repeated at least 3 times. DRG, dorsal root ganglion; hNa V 1.9, human Na V 1.9; PRMT7, protein arginine methyltransferase 7.
Techniques Used: Infection, Expressing, Transfection, Fractionation, Western Blot
Figure Legend Snippet: Protein arginine methyltransferase 7 modulates Na V 1.9 currents by binding and methylating hLoop1. (A) Schematic representation of one deletion mutant and 4 single-alanine–scanning constructs spanning the region between residues 563 and 572 used in the Y2H assay. The percentage of yeast transformant growth on QDO medium was analysed correspondingly by one-way ANOVA (n = 3). *** P < 0.001, n.s., no significance. (B) Immunoblotting analysis showing the enhanced monomethylation of hLoop1 in hPRMT7-overexpressing cells with the indicated antibodies. (C) Immunoblotting with the indicated antibodies showed decreased MMA levels of hLoop1 in hPRMT7-knockdown cells and increased MMA levels of hLoop1 in hPRMT7-overexpressing cells. (D) Immunoprecipitation of FLAG-tagged wild-type (WT) R519A, R521A, or R519A/R521A hLoop1 proteins expressed in HEK293T cells using anti-FLAG antibodies. The methylation signals and target bands were immunoblotted with the indicated antibodies. (E) Representative whole-cell hNaV1.9 currents evoked by voltage from Scn11a −/− mouse small DRG neurons electroporated with the indicated groups. (F) Current–voltage relationships of the indicated experimental groups. The peak current density (normalized by membrane capacitance) was statistically analysed (hNa V 1.9-4A, n = 14; hNa V 1.9-4A+hPRMT7, n = 12; hNa V 1.9-R519A, n = 10; hNa V 1.9-R519A+hPRMT7, n = 9), and significant differences were tested by two-way ANOVA. ANOVA, analysis of variance; DRG, dorsal root ganglion; hNa V 1.9, human Na V 1.9; MMA, monomethylarginine; PRMT7, protein arginine methyltransferase 7; QDO, quadruple dropout; WCLs, whole-cell lysates; Y2H, yeast two-hybrid.
Techniques Used: Binding Assay, Mutagenesis, Construct, Y2H Assay, Western Blot, Immunoprecipitation, Methylation
Figure Legend Snippet: DS-437 reduced DRG neuronal excitability and relieved pain hypersensitivity in Scn11a A796G/A796G mice. (A) Current-clamp responses to a 200-ms depolarizing current of 200 pA in representative Scn11a +/+ mouse DRG neurons and Scn11a A796G/A796G mouse DRG neurons with DS-437 or control. (B) Rheobase, (C) resting membrane potential (RMP), and (D) V threshold (the threshold at which AP takeoff occurs) showed no significant changes in DRG neurons treated with or without DS-437. Data were statistically analysed by one-way ANOVA; * P < 0.05 compared with the control. (E) Comparison of the average spike numbers of repetitive action potentials (APs) fired in response to the 200-ms current injection ranging from 0 to 225 pA in DRG neurons (Na V 1.9-WT + control, n = 21; Na V 1.9-WT + 100 μM DS-437, n = 22; Na V 1.9-KI + control, n = 30; Na V 1.9-KI + 10 μM DS-437, n = 22; Na V 1.9-KI + 100 μM DS-437, n = 24). Significant differences were tested by two-way ANOVA, followed by a post hoc Bonferroni test; DS-437 × current: F(36, 1041) = 2.049, P = 0.0003; DS-437: F(3, 1041) = 50.86, P < 0.0001; current: F(9, 1041) = 74.58, P < 0.0001; ** P < 0.01 and *** P < 0.001 compared with the control. (F) The duration of licking and lifting behaviours in Na V 1.9-KI mice and Na V 1.9-WT in the 45 minutes after intraplantar administration of formalin to the hind paws binned at 5-min intervals. (G) Data from 2 phases of the formalin test are summarized. Phase I: 0 to 10 minutes. Phase II: 10 to 45 minutes (saline, n = 6; DS-437, n = 6). Significant differences were tested by one-way ANOVA; * P < 0.05 and ** P < 0.01 compared with saline. (H) Heat threshold was assessed using the hot-plate test. (I) Mechanical withdrawal threshold was tested by applying von Frey filaments (saline, n = 6; DS-437, n = 6). Significant differences were tested by two-way ANOVA; * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with saline. ANOVA, analysis of variance; DRG, dorsal root ganglion.
Techniques Used: Injection, Hot Plate Test
Figure Legend Snippet: Proposed working model of PRMT7-mediated Na V 1.9 trafficking and cellular excitability. The PRMT7 C-terminal domain interacts with residues 563 to 566 of hLoop1 and methylates arginine 519 (R519 me) in this loop using S-adenosyl-L-methionine (AdoMet) as a methyl donor to produce S-adenosylhomocysteine (AdoHcy). Human Na V 1.9; R519 me is involved in the regulation of Na V 1.9 trafficking to the cell surface through an undefined mechanism. Consequently, altered cell surface expression of Na V 1.9 increases sodium current density, leading to hyperexcitability of DRG neurons. DRG, dorsal root ganglion; PRMT7, protein arginine methyltransferase 7.
Techniques Used: Expressing
Related Articles
other:Article Title: A disease mutation reveals a role for Na V 1.9 in acute itch Article Snippet: Primary antibodies used were |
